(Reuters) – CAMP4 Therapeutics, a biopharmaceutical firm backed by healthcare giant Kaiser Permanente on Thursday raised $75 million after pricing its U.S. initial public offering (IPO).
CAMP4 sold 6.82 million shares in the IPO for $11 per share, the company said in a statement.
(Reporting by Pretish M J in Bengaluru)
